Publicaciones

Aptámeros
  • Pastor F., Kolonias D., Giangrande P., Gilboa E.* Induction of tumor immunity by targeted inhibition of nonsense mediated mRNA decay. Nature 2010; 465, 227–230. IF (2010): 36.101; Lugar: 1/56; Multidisciplinary Sciences 1ercuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Pastor F., Kolonias D., McNamara J., Gilboa E.* Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific aptamers. Mol Ther. 2011 Oct 19(10):1878-86. IF (2011): 7.041; Lugar: 9/160; Biotech- nology and applied microbiology; 1ercuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M.* BiovaxID: a customized idioty- pe vaccine for the treatment of B-cell lymphoma. Expert Rev Vaccines. 2011 Dec;10(12):1661-9. (Review) IF 4.219; Lugar: 33/137; Immunology; 1ercuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Gilboa E,* Mc Namara J, Pastor FUse of oligonucleotide aptamer ligands to modulate the function of immu- ne receptors. Clinical Cancer Research. 2013 Mar 1;19(5):1054-62 IF (2012) 7.837; Lugar: 12/197; Oncology; 1ercuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Pastor F,* Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi MCD28 aptamers as powerful immune response modulators. Mol Ther. 2013 Jun 11 IF (2012) 7.041; Lugar: 9/160; Biotechnology and applied microbiology; 1ercuartil.
    ABSTRACT CORTESÍA DE PUBMED

Péptidos
  • Hermida, N., B. Lopez, A. Gonzalez, J. Dotor, J. J. Lasarte, P. Sarobe, F. Borras-Cuesta, and J. Diez.* 2009. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81:601-609. IF 6.113; Lugar: 12/124; Cardiac and cardiovas- cular systems; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Llopiz, D., J. Dotor, N. Casares, J. Bezunartea, N. Diaz-Valdes, M. Ruiz, F. Aranda, P. Berraondo, J. Prieto, J. J. Lasarte, F. Borras-Cuesta, and P. Sarobe.* 2009. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 125:2614-2623. IF 5.474; Lugar: 23/197; On- cology; 1er  cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Casares, N., F. Rudilla, L. Arribillaga, D. Llopiz, J. I. Riezu-Boj, T. Lozano, J. Lopez-Sagaseta, L. Guembe, P. Sarobe, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte.* 2010. A peptide inhibitor of FOXP3 impairs regula- tory T cell activity and improves vaccine efficacy in mice. J Immunol 185:5150-5159. IF 5.860; Lugar: 24/137; Immunology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Diaz-Valdes, N., M. Basagoiti, J. Dotor, F. Aranda, I. Monreal, J. I. Riezu-Boj, F. Borras-Cuesta, P. Sarobe, and E. Feijoo.* 2011. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 71:812-821. IF 8.576; Lugar: 11/197; Oncology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Diaz-Valdes, N., L. Manterola, V. Belsue, J. I. Riezu-Boj, E. Larrea, I. Echeverria, D. Llopiz, J. Lopez-Sagas- eta, H. Lerat, J. M. Pawlotsky, J. Prieto, J. J. Lasarte, F. Borras-Cuesta, and P. Sarobe.* 2011. Improved den- dritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 53:23-31. IF 11.4; Lugar: 2/74; Gastroenterology and hepatology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

Moléculas pequeñas
  • 4D'Abramo, M.; Rabal, O.; Oyarzabal, J.;* Gervasio, F.L.* Conformational Selection versus Induced Fit in Kinases: The Case of PI3K-?. Angew Chem Int Ed Engl., 2012, 51, 642 – 646; IF: 13.734 (2012); Lugar: 7/152; Chemistry, multidisciplinary; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Rabal, O.; Oyarzabal, J.Biologically Relevant Chemical Space Navigator: From Patent and Structure-Activity Relationship Analysis to Library Acquisition and Design. Journal of Chemical Information and Modeling, 2012, 52, 3123 – 3137. IF: 4.304 (2012); Lugar: 3/100; Computer science, interdisciplinary applications; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Ugarte, A.; Gil-Bea, F.; García-Barroso, C.; Cedazo-Minguez, A.; Ramírez, M. J.; Franco R.; García-Osta, A.; Oyarzabal, J.;* Cuadrado-Tejedor, M.* Decreased levels of cGMP in CSF are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathology Applied Neurobiololgy. 2015, 41, 471-482;  IF: 3.927 (2014); Lugar: 33/192; Neurology, clinical; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Orbe, J.; Sanchez-Arias, J. A.; Rabal, O.; Rodríguez, J. A.; Salicio, A.; Ugarte, A.; Belzunce, M.; Xu, M.; Wu, W.; Tan, H.; Ma, H.; Paramo, J. A.;* Oyarzabal, J.* Design, synthesis and biological evaluation of novel matrix metalloproteinase inhibitors as  potent antihemorrhagic agents: from hit identification to an optimized lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488; IF: 5.447 (2014); Lugar: 3/59; Chemistry, medicinal; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Orbe, J.; Rodríguez, J. A; Sanchez-Arias, J. A; Salicio, A.; Belzunce, M.; Ugarte, A; Chang, H.C.Y.; Rabal, O; Oyarzabal, J;* Paramo, J. A* Novel Discovery and safety profiling of a potent pre-clinical candidate, 4-[4-[[(3R)-3(hydroxycarbamoyl) -8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methyl-benzamide (CM-352), for the prevention and treatment of hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957; IF: 5.447 (2014); Lugar: 3/59; Chemistry, medicinal; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED



"Our goal is to discover new molecular therapies that can meet unresolved medical requirements, based on new targets and/or mechanisms of action provided by the researchers for CIMA and Clínica Universidad de Navarra", Dr. Julen Oyarzabal, Program Director..

Contact

Contact:
Cristina Canciani
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 2013
canciani@unav.es